|
Age, years
| | |
*0.003
|
|
Mean age (SD)
|
66.92 (9.7)
|
62.74 (11.41)
| |
|
Gender
| | |
0.415
|
|
Male
|
182 (65.2)
|
42 (60.0)
| |
|
Female
|
97 (34.8)
|
28 (40.0)
|
|
Treatment arm in TES trial
| | |
0.610
|
|
Intervention
|
149 (53.4)
|
35 (50)
| |
|
Control
|
130 (46.6)
|
35 (50)
|
|
ECOG PSa
| | |
0.714
|
|
0
|
67 (24.0)
|
15 (21.4)
| |
|
1
|
87 (31.2)
|
18 (25.7)
|
|
2
|
8 (2.9)
|
3 (4.3)
|
|
Missing
|
117 (41.9)
|
34 (48.6)
|
|
Primary tumor location
| | |
0.695
|
|
Right-sided
|
84 (30.1)
|
23 (32.9)
| |
|
Left-sided
|
192 (68.8)
|
47 (67.1)
|
|
Missing
|
3 (1.1)
|
–
|
|
Chemotherapy regimen
| | |
0.875
|
|
Capecitabine
|
59 (21.1)
|
13 (18.6)
| |
|
CAPOX
|
190 (68.1)
|
50 (71.4)
|
|
FOLFOX/Other
|
27 (9.7)
|
7 (10.0)
|
|
Missing
|
3 (1.1)
|
–
|
|
Number of comorbidities
| | |
0.980
|
|
Mean (SD)
|
2.33 (1.78)
|
2.33 (2.00)
| |
|
Marital status
| | |
0.369
|
|
Married/domestic partnership
|
207 (74.2)
|
49 (70.0)
| |
|
Unmarried/divorced/widowed
|
68 (24.4)
|
21 (30.0)
|
|
Missing
|
4 (1.4)
|
–
|
|
Number of persons in household
| | |
0.615
|
|
1
|
49 (17.6)
|
13 (18.6)
| |
|
2
|
177 (63.4)
|
42 (60.0)
|
|
3
|
23 (8.2)
|
4 (5.7)
|
|
> 3
|
26 (9.3)
|
11 (15.7)
|
|
Missing
|
4 (1.4)
|
–
|
|
Educationb
| | |
*0.041
|
|
Low
|
17 (6.1)
|
2 (2.9)
| |
|
Middle
|
184 (65.9)
|
39 (55.7)
|
|
High
|
72 (25.8)
|
29 (41.4)
|
|
Missing
|
6 (2.2)
|
0 (0)
|
|
Currently working
| | |
0.949
|
|
Yes
|
65 (23.3)
|
16 (22.9)
| |
|
No/retired
|
210 (75.3)
|
54 (77.1)
|
|
Missing
|
4 (1.4)
|
–
|
|
Time from diagnosis primary tumor until start study
| | |
0.848
|
|
< 1.5 months
|
94 (33.7)
|
22 (31.4)
| |
|
1.5–10 months
|
89 (31.9)
|
25 (35.7)
|
|
> 10 months
|
93 (33.3)
|
23 (32.9)
|
|
Missing
|
3 (1.1)
|
–
|
|
Time from diagnosis metastatic disease until start study
| | |
0.666
|
|
< 1.0 months
|
95 (34.1)
|
27 (38.6)
| |
|
1.0–2.5 months
|
87 (31.2)
|
23 (32.9)
|
|
> 2.5 months
|
94 (33.7)
|
20 (28.6)
|
|
Missing
|
3 (1.1)
|
–
|
|
Prior cancer related treatment
|
|
No
|
85 (30.5)
|
23 (32.9)
|
0.699
|
|
Yes
|
194 (69.5
|
47 (67.1)
|
|
Prior treatment metastases
|
|
No
|
214 (76.7)
|
56 (80.0)
|
0.657
|
|
Yes
|
62 (22.2)
|
14 (20.0)
|
|
Missing
|
3 (1.1)
|
–
|
|
Number of organs with metastases
| | |
0.599
|
|
Median
|
2
|
2
| |
|
Total number of metastases
|
|
Median
|
11.5
|
13.0
|
0.877
|
|
Participation in other trials
| | |
0.718
|
|
No
|
170 (60.9)
|
41 (58.6)
| |
|
Yes
|
109 (39.1)
|
29 (41.4)
|
|
HADS
|
|
Total score
|
9.10 (6.30)
|
11.17 (7.47)
|
*0.020
|
|
Distress on HADS No
|
208 (74.6)
|
44 (62.9)
|
*0.033
|
|
Yes
|
67 (24.0)
|
26 (37.1)
| |
|
Missing
|
4 (1.4)
|
–
|
|
DT/PL
|
|
DT score
|
4.33 (2.68)
|
4.75 (2.40)
|
*0.242
|
|
Total of physical problems
|
5.78 (6.29)
|
7.37 (4.61)
|
*0.020
|
|
Total of emotional problems
|
1.95 (2.11)
|
2.74 (2.57)
|
*0.009
|
|
Need to talk to professional No
|
257 (92.1)
|
58 (82.9)
|
*0.023
|
|
Yes
|
22 (7.9)
|
12 (17.1)
| |
|
Quality of life (QLQ-C30)
|
|
Physical functioning
|
74.84 (20.30)
|
72.76 (21.88)
|
0.451
|
|
Role functioning
|
65.69 (30.70)
|
58.81 (30.13)
|
*0.010
|
|
Emotional functioning
|
78.25 (18.12)
|
72.86 (21.41)
|
*0.095
|
|
Cognitive functioning
|
89.44 (14.97)
|
86.90 (16.76)
|
*0.219
|
|
Social functioning
|
78.08 (23.89)
|
69.05 (31.38)
|
*0.010
|
|
Global QOL
|
63.77 (21.73)
|
60.00 (21.78)
|
*0.197
|
|
Pain score
|
16.00 (23.75)
|
40.15 (26.57)
|
*0.174
|
|
Fatigue score
|
25.00 (16.67)
|
45.08 (44.44)
|
*0.009
|
